EligibleTrials

Clinical trials recruiting for Solid Carcinoma

6
Recruiting trials
20
US states with sites
7
Countries
0%
Accept healthy volunteers

Phase breakdown

Phase 1 5Phase 2 5Phase 3 1

Drugs and treatments being studied

InterventionTrials
18F-TRX1
ALX1481
Cetuximab1
DM0021
DM0051
FOLFIRI1
FOLFOX6/FOLFOX71
Fam-Trastuzumab Deruxtecan-Nxki1
Gemcitabine1
Nab-paclitaxel1
Panitumumab1
S2416561

Where trials are recruiting (top US states)

StateRecruiting trials
Texas4
California3
Arizona2
Colorado2
Michigan2
Minnesota2
North Carolina2
Virginia2
Alabama1
Connecticut1
District of Columbia1
Florida1

Top cities

Houston, Texas 3San Francisco, California 3Aurora, Colorado 2Fairfax, Virginia 2Minneapolis, Minnesota 2Birmingham, Alabama 1Boston, Massachusetts 1Chicago, Illinois 1Cleveland, Ohio 1Dallas, Texas 1

Self-screener

Recruiting trials

Related conditions

Trials recruiting for Solid Carcinoma often also study these conditions. Each links to its own recruiting-trial list.

Prostate cancer 1234Lung cancer 2180Thyroid Cancer 21Colorectal Neoplasms 61Colorectal cancer 1359Triple-negative breast cancer 138Thyroid Carcinoma 3Stage IVB Prostate Cancer AJCC v8 27Stage IV Renal Cell Cancer AJCC v8 9Stage III Renal Cell Cancer AJCC v8 6

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Solid Carcinoma trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.